Trial record 3 of 6 for:    azixa

Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by Myrexis Inc..
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Myrexis Inc.
ClinicalTrials.gov Identifier:
NCT00635557
First received: March 6, 2008
Last updated: March 24, 2011
Last verified: March 2011
  Purpose

This is an open-label, dose finding, multiple-dose study in subjects with recurring/relapsing glioblastoma multiforme. Three dose levels of MPC-6827 will be administered with carboplatin to three separate cohorts. Study endpoints will include determination of the maximum tolerated dose, dose limiting toxicities, and evaluation of evidence of anti-tumor activity of MPC-6827 when given with carboplatin.


Condition Intervention Phase
Glioblastoma Multiforme
Drug: MPC-6827 + Carboplatin
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Dose Finding Phase 1 Study of the Treatment of Recurrent/Relapsed Glioblastoma Multiforme With MPC-6827 in Combination With Carboplatin

Resource links provided by NLM:


Further study details as provided by Myrexis Inc.:

Primary Outcome Measures:
  • Maximum tolerated dose [ Time Frame: After each cohort is enrolled and all subjects have completed 1 cycle ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Pharmacokinetics [ Time Frame: Cycle 1 only ] [ Designated as safety issue: No ]
  • Antitumor activity [ Time Frame: Screening, end of each cycle, end of study ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: March 2008
Estimated Study Completion Date: August 2011
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: MPC-6827 + Carboplatin
    MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Carboplatin at AUC4 administered by intravenous infusion over 1 hour on Day 1 of each 4 week cycle.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically proven WHO Grade IV glioblastoma multiforme at time of diagnosis or relapse
  • Prior treatment with radiotherapy and temozolomide
  • Evidence of measurable recurrent or residual primary tumor by contrast-enhanced MRI
  • Be a minimum of 4 weeks since prior surgical resection, major surgical procedure, radiation therapy or cytotoxic chemotherapy (6 weeks since prior BCNU or CCNU)
  • Have a Performance Scale of Karnofsky > 60%, ECOG < 2 or WHO < 2
  • If steroids are needed, be on a stable or decreasing dose of steroids for at least 1 week

Exclusion Criteria:

  • Hypersensitivity to Cremophor EL
  • Have evidence of current/active intratumor hemorrhage by MRI
  • Have greater than second relapse
  • Have had prior treatment with platinum-based chemotherapy
  • Have cardiovascular disease
  • Have cerebrovascular disease
  • Have uncontrolled hypertension
  • Have a cardiac ejection fraction < 50%
  • Have Troponin-I elevated above the normal range
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00635557

Locations
United States, California
The Angeles Clinic and Research Institute
Los Angeles, California, United States, 90025
United States, Georgia
Emory University
Atlanta, Georgia, United States, 30322
United States, New York
Mt. Sinai School of Medicine
New York, New York, United States, 10029
United States, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Utah
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah, United States, 84112
Sponsors and Collaborators
Myrexis Inc.
Investigators
Study Director: Andrew P. Beelen, MD Myrexis Inc.
  More Information

No publications provided

Responsible Party: Andrew P. Beelen, MD / Sr. Director of Clinical Research, Myrexis Inc.
ClinicalTrials.gov Identifier: NCT00635557     History of Changes
Other Study ID Numbers: MPC-6827-07-004, MPC-6827 GBM
Study First Received: March 6, 2008
Last Updated: March 24, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Myrexis Inc.:
Recurrent
Relapsed
Glioblastoma
Multiforme

Additional relevant MeSH terms:
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Carboplatin
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 30, 2014